Skip to content
Roboearth – Lifestyle
Author:
Cingulate Inc.
Cingulate Receives Complete Response Letter from FDA for CTx-1301
June 2, 2026
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
May 14, 2026
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
March 18, 2026